Business Description
Edwards Lifesciences Corp
NAICS : 339113
SIC : 3842
ISIN : US28176E1082
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.29 | |||||
Equity-to-Asset | 0.74 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | 0.38 | |||||
Interest Coverage | 102.74 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 10.31 | |||||
Beneish M-Score | -1.21 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.4 | |||||
3-Year EBITDA Growth Rate | 20.6 | |||||
3-Year EPS without NRI Growth Rate | 10.5 | |||||
3-Year FCF Growth Rate | 0.3 | |||||
3-Year Book Growth Rate | 14.7 | |||||
Future 3-5Y Total Revenue Growth Rate | 2.65 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 62.39 | |||||
9-Day RSI | 64.8 | |||||
14-Day RSI | 61.75 | |||||
6-1 Month Momentum % | -20.29 | |||||
12-1 Month Momentum % | 2.88 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.46 | |||||
Quick Ratio | 2.89 | |||||
Cash Ratio | 2.29 | |||||
Days Inventory | 254.81 | |||||
Days Sales Outstanding | 42.33 | |||||
Days Payable | 44.32 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.3 | |||||
Shareholder Yield % | 3.56 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 75.97 | |||||
Operating Margin % | 27.4 | |||||
Net Margin % | 63.02 | |||||
FCF Margin % | 7.43 | |||||
ROE % | 55.59 | |||||
ROA % | 40.35 | |||||
ROIC % | 22.84 | |||||
ROC (Joel Greenblatt) % | 60.77 | |||||
ROCE % | 18.91 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 10.3 | |||||
Forward PE Ratio | 29.35 | |||||
PE Ratio without NRI | 26.72 | |||||
Shiller PE Ratio | 31.44 | |||||
Price-to-Owner-Earnings | 11.5 | |||||
PEG Ratio | 1.52 | |||||
PS Ratio | 6.53 | |||||
PB Ratio | 4.41 | |||||
Price-to-Tangible-Book | 6.03 | |||||
Price-to-Free-Cash-Flow | 87.55 | |||||
Price-to-Operating-Cash-Flow | 53.29 | |||||
EV-to-EBIT | 22.62 | |||||
EV-to-Forward-EBIT | 24.28 | |||||
EV-to-EBITDA | 20.79 | |||||
EV-to-Forward-EBITDA | 22.01 | |||||
EV-to-Revenue | 5.81 | |||||
EV-to-Forward-Revenue | 6.45 | |||||
EV-to-FCF | 78.23 | |||||
Price-to-Projected-FCF | 2.07 | |||||
Price-to-DCF (Earnings Based) | 0.95 | |||||
Price-to-DCF (FCF Based) | 6.45 | |||||
Price-to-Median-PS-Value | 0.72 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.91 | |||||
Price-to-Graham-Number | 2.68 | |||||
Price-to-Net-Current-Asset-Value | 12.74 | |||||
Price-to-Net-Cash | 41.24 | |||||
Earnings Yield (Greenblatt) % | 4.42 | |||||
FCF Yield % | 1.16 | |||||
Forward Rate of Return (Yacktman) % | 16.04 |